These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 34688262)
1. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature. Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262 [TBL] [Abstract][Full Text] [Related]
2. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study. Fang X; Zhong C; Weng S; Hu H; Wang J; Xiao Q; Wang J; Sun L; Xu D; Liao X; Dong C; Zhang S; Li J; Ding K; Yuan Y BMC Cancer; 2023 Jul; 23(1):676. PubMed ID: 37464378 [TBL] [Abstract][Full Text] [Related]
3. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. Wang C; Chevalier D; Saluja J; Sandhu J; Lau C; Fakih M Oncologist; 2020 Aug; 25(8):e1188-e1194. PubMed ID: 32406541 [TBL] [Abstract][Full Text] [Related]
4. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F; Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911 [TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970 [TBL] [Abstract][Full Text] [Related]
6. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142 [TBL] [Abstract][Full Text] [Related]
7. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report. Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109 [TBL] [Abstract][Full Text] [Related]
8. Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer. He WZ; Wang L; Yin CX; Yi JH; Jin YN; Jiang C; Guo GF; Xia LP Cancer Med; 2023 Mar; 12(6):6488-6498. PubMed ID: 36373163 [TBL] [Abstract][Full Text] [Related]
9. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature. Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study. Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036 [TBL] [Abstract][Full Text] [Related]
11. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209 [TBL] [Abstract][Full Text] [Related]
12. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report. Kikuchi K; Ogawa M; Sasaki A J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349 [TBL] [Abstract][Full Text] [Related]
14. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791 [TBL] [Abstract][Full Text] [Related]
15. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC. Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M Front Immunol; 2024; 15():1372279. PubMed ID: 38756778 [TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. Yang K; Han L; Wu S; Qu X; Li Q; Zhao C; Zhou J; Jin X; Wang Y; Yan D; Cheng Z; Hua Y; Zhang Y; Ge Y; Sun J; Deng W; Zhao L; Zhao Y Cancer Immunol Immunother; 2022 Jun; 71(6):1443-1451. PubMed ID: 34689233 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope? Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528 [TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report. Yang Y; Xu L; Wang D; Hui B; Li X; Zhou Y; Chen X; Gu Y Immunotherapy; 2021 Nov; 13(16):1317-1323. PubMed ID: 34369830 [TBL] [Abstract][Full Text] [Related]
19. Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. Cousin S; Cantarel C; Guegan JP; Gomez-Roca C; Metges JP; Adenis A; Pernot S; Bellera C; Kind M; Auzanneau C; Le Loarer F; Soubeyran I; Bessede A; Italiano A Clin Cancer Res; 2021 Apr; 27(8):2139-2147. PubMed ID: 33495314 [TBL] [Abstract][Full Text] [Related]
20. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a Gong J; Wang C; Lee PP; Chu P; Fakih M J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]